Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Garuda Therapeutics has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in March 2025.
Garuda Therapeutics's investors include OrbiMed, Cormorant Asset Management, Resilience, Aisling Capital, Alexandria Venture Investments.
Garuda Therapeutics is headquartered in Cambridge, United States.
Garuda Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Garuda Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Garuda Therapeutics — Funding & Investors." VCBacked, March 4, 2025, https://www.vcbacked.co/company/garuda-therapeutics. Accessed September 10, 2026.
VCBacked. (2025). Garuda Therapeutics — Funding & Investors. Retrieved September 10, 2026, from https://www.vcbacked.co/company/garuda-therapeutics
{{cite web |title=Garuda Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/garuda-therapeutics |website=VCBacked |access-date=September 10, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated